Rapid analysis of local data to inform off-label tocilizumab use early in the COVID-19 pandemic

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Morgan, C.E.
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
  • Rimland, C.A.
    • Affiliation: University of North Carolina at Chapel Hill
  • Bell, G.J.
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
  • Kim, M.K.
    • Affiliation: School of Medicine, Division of Infectious Diseases
  • Hedrick, T.
    • Affiliation: UNC Medical Center
  • Marx, A.
    • Affiliation: UNC Medical Center
  • Bramson, B.
    • Affiliation: School of Medicine, Division of Infectious Diseases
  • Swygard, H.
    • Affiliation: School of Medicine, Division of Infectious Diseases
  • Napravnik, S.
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
  • Schmitz, J.L.
    • Affiliation: School of Medicine, Department of Pathology and Laboratory Medicine
  • Carson, S.S.
    • Affiliation: School of Medicine, Department of Medicine, Division of Pulmonary Diseases and Critical Care Medicine
  • Fischer, W.A.
    • Affiliation: School of Medicine, Department of Medicine, Division of Pulmonary Diseases and Critical Care Medicine
  • Eron, J.J.
    • Affiliation: School of Medicine, Division of Infectious Diseases
  • Gay, C.L.
    • Affiliation: School of Medicine, Division of Infectious Diseases
  • Parr, J.B.
    • Affiliation: School of Medicine, Division of Infectious Diseases
Abstract
  • The interleukin-6 receptor antagonist tocilizumab became widely used early in the coronavirus disease 2019 (COVID-19) pandemic based on small observational studies that suggested clinical benefit in COVID-19 patients with a hyperinflammatory state. To inform our local treatment algorithms in the absence of randomized clinical trial results, we performed a rapid analysis of the first 11 hospitalized COVID-19 patients treated with tocilizumab at our academic medical center. We report their early clinical outcomes and describe the process by which we assembled a team of diverse trainees and stakeholders to extract, analyze, and disseminate data during a time of clinical uncertainty.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
Journal title
  • Healthcare
Journal volume
  • 9
Journal issue
  • 4
Language
  • English
ISSN
  • 2213-0764

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details main.pdf 2021-11-05 Public Download